Cannabinoid 1 (CB ) receptor arrestin subtype-selectivity and phosphorylation dependence.

Jamie J Manning, Gabriel Rawcliffe, David B Finlay, Michelle Glass
Author Information
  1. Jamie J Manning: Department of Pharmacology and Toxicology, School of Biomedical Sciences, University of Otago, Dunedin, New Zealand. ORCID
  2. Gabriel Rawcliffe: Department of Pharmacology and Toxicology, School of Biomedical Sciences, University of Otago, Dunedin, New Zealand. ORCID
  3. David B Finlay: Department of Pharmacology and Toxicology, School of Biomedical Sciences, University of Otago, Dunedin, New Zealand. ORCID
  4. Michelle Glass: Department of Pharmacology and Toxicology, School of Biomedical Sciences, University of Otago, Dunedin, New Zealand. ORCID

Abstract

BACKGROUND AND PURPOSE: Arrestin or G protein bias may be desirable for novel cannabinoid therapeutics. Arrestin-2 and arrestin-3 translocation to CB receptor have been suggested to mediate different functions that may be exploited with biased ligands. Here, the requirement of a recently described phosphorylation motif 'pxxp' (where 'p' denotes phosphorylatable serine or threonine and 'x' denotes any other amino acid) within the CB receptor C-terminus for interaction with different arrestin subtypes was examined.
EXPERIMENTAL APPROACH: Site-directed mutagenesis was conducted to generate nine different phosphorylation-impaired CB receptor C-terminal mutants. Bioluminescence resonance energy transfer (BRET) was employed to measure Arrestin-2/3 translocation and G protein dissociation of a high efficacy agonist for each mutant. Immunocytochemistry was used to quantify receptor expression.
KEY RESULTS: The effects of each mutation were shared for Arrestin-2 and arrestin-3 translocation to CB receptor pxxp motifs are partially required for Arrestin-2/3 translocation, but translocation was not completely inhibited until all phosphorylation sites were mutated. The rate of arrestin translocation was reduced with simultaneous mutation of S425 and S429. Desensitisation of G protein dissociation was inhibited in different mutants proportional to the extent of their respective loss of arrestin translocation.
CONCLUSIONS AND IMPLICATIONS: These data do not support the existence of an 'essential' pxxp motif for arrestin translocation to CB receptor. These data also identify that Arrestin-2 and arrestin-3 have equivalent phosphorylation requirements within the CB receptor C-terminus, suggesting arrestin subtype-selective biased ligands may not be viable and that different regions of the C-terminus contribute differently to arrestin translocation.

Keywords

References

  1. PeerJ. 2016 Mar 21;4:e1835 [PMID: 27018161]
  2. Mol Pharmacol. 2016 Jun;89(6):618-29 [PMID: 27009233]
  3. Front Pharmacol. 2019 Apr 10;10:350 [PMID: 31024316]
  4. Br J Pharmacol. 2023 Feb;180(3):369-382 [PMID: 36250246]
  5. Neuropharmacology. 2008 Jan;54(1):36-44 [PMID: 17681354]
  6. Cell. 2022 May 12;185(10):1661-1675.e16 [PMID: 35483373]
  7. ACS Chem Neurosci. 2019 Oct 16;10(10):4350-4360 [PMID: 31513380]
  8. Br J Pharmacol. 2022 May;179(10):2223-2239 [PMID: 34811740]
  9. Br J Pharmacol. 2022 Aug;179(15):3907-3913 [PMID: 35673806]
  10. Biochem Pharmacol. 2020 May;175:113871 [PMID: 32088263]
  11. Front Cell Neurosci. 2022 Jan 17;15:814547 [PMID: 35110998]
  12. Behav Pharmacol. 2008 Jul;19(4):298-307 [PMID: 18622177]
  13. Front Immunol. 2020 Apr 22;11:720 [PMID: 32391018]
  14. Mol Pharmacol. 2015 Oct;88(4):825-35 [PMID: 25969388]
  15. Nature. 2014 Aug 14;512(7513):218-222 [PMID: 25043026]
  16. Cell. 2019 Jan 24;176(3):448-458.e12 [PMID: 30639101]
  17. Arch Pharm Res. 2016 Mar;39(3):293-301 [PMID: 26825061]
  18. J Neurochem. 1999 Aug;73(2):493-501 [PMID: 10428044]
  19. J Neurosci. 1999 May 15;19(10):3773-80 [PMID: 10234009]
  20. Pharmacol Rev. 2006 Sep;58(3):389-462 [PMID: 16968947]
  21. ACS Chem Neurosci. 2016 Sep 21;7(9):1241-54 [PMID: 27421060]
  22. Neuropharmacology. 2019 Apr;148:151-159 [PMID: 30629988]
  23. J Recept Signal Transduct Res. 2013 Dec;33(6):367-79 [PMID: 24094141]
  24. J Neurosci. 2014 Apr 9;34(15):5152-63 [PMID: 24719095]
  25. Curr Protoc Pharmacol. 2015 Sep 01;70:2.14.1-2.14.14 [PMID: 26331887]
  26. Neuropharmacology. 2021 Aug 1;193:108611 [PMID: 34000272]
  27. Br J Pharmacol. 2021 Oct;178 Suppl 1:S27-S156 [PMID: 34529832]
  28. Br J Pharmacol. 2019 Dec;176(24):4653-4665 [PMID: 31412133]
  29. Br J Pharmacol. 2012 Apr;165(8):2652-9 [PMID: 22014214]
  30. Sci Signal. 2011 Aug 9;4(185):ra52 [PMID: 21868358]
  31. Cell Signal. 2018 Jan;41:17-24 [PMID: 28711719]
  32. Nat Commun. 2019 Mar 19;10(1):1261 [PMID: 30890705]
  33. Sci Signal. 2018 Jul 17;11(539): [PMID: 30018083]
  34. Clin Exp Pharmacol Physiol. 2008 Nov;35(11):1377-82 [PMID: 18565191]
  35. Br J Pharmacol. 2017 Aug;174(15):2545-2562 [PMID: 28516479]
  36. Br J Pharmacol. 2018 Feb;175(3):407-411 [PMID: 29350411]
  37. Sci Rep. 2020 Jul 23;10(1):12263 [PMID: 32704081]
  38. Nat Commun. 2022 Jan 25;13(1):487 [PMID: 35078997]
  39. J Pharmacol Exp Ther. 2018 May;365(2):437-446 [PMID: 29549157]
  40. Nat Rev Mol Cell Biol. 2018 Oct;19(10):638-653 [PMID: 30104700]
  41. J Neurochem. 2008 Jul;106(1):70-82 [PMID: 18331587]

Grants

  1. 19/242/Health Research Council of New Zealand
  2. /University of Otago

MeSH Term

Arrestins
beta-Arrestin 1
beta-Arrestin 2
beta-Arrestins
Cannabinoids
GTP-Binding Proteins
Phosphorylation
Receptor, Cannabinoid, CB1
Humans

Chemicals

Arrestins
beta-Arrestin 1
beta-Arrestin 2
beta-Arrestins
Cannabinoids
GTP-Binding Proteins
Receptor, Cannabinoid, CB1

Word Cloud

Created with Highcharts 10.0.0translocationreceptorarrestinCBdifferentphosphorylationGproteinmayarrestin-3C-terminusANDbiascannabinoidbiasedligandsmotifdenoteswithinmutantsarrestin-2/3dissociationmutationarrestin-2pxxpinhibiteddataBACKGROUNDPURPOSE:ArrestindesirablenoveltherapeuticsArrestin-2suggestedmediatefunctionsexploitedrequirementrecentlydescribed'pxxp''p'phosphorylatableserinethreonine'x'aminoacidinteractionsubtypesexaminedEXPERIMENTALAPPROACH:Site-directedmutagenesisconductedgenerateninephosphorylation-impairedC-terminalBioluminescenceresonanceenergytransferBRETemployedmeasurehighefficacyagonistmutantImmunocytochemistryusedquantifyexpressionKEYRESULTS:effectssharedmotifspartiallyrequiredcompletelysitesmutatedratereducedsimultaneousS425S429DesensitisationproportionalextentrespectivelossCONCLUSIONSIMPLICATIONS:supportexistence'essential'alsoidentifyequivalentrequirementssuggestingsubtype-selectiveviableregionscontributedifferentlyCannabinoid1subtype-selectivitydependenceCB1GPCR

Similar Articles

Cited By (5)